AMPH vs VTRS
AMPH: Amphastar manufactures technically complex generic and proprietary injectable, inhalation, and intranasal drugs with high barriers to entry, leveraging proprietary formulation and manufacturing capabilities to compete in high-margin, supply-constrained markets. VTRS: Viatris is a global healthcare company providing a broad range of high-quality, affordable medicines across both developed and emerging markets.
Side-by-side fundamentals
| Metric | AMPH | VTRS | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $20.78 | $16.43 | |
| Market cap as of 2026-08-09 | $916M | $19.1B | |
| P/E as of 2026-08-09 | 11.56 | n/a | |
| PEG as of 2026-08-09 | -1.94 | 1.68 | AMPH lower |
| Net margin as of 2026-08-09 | +11.0% | -2.8% | AMPH higher |
| Gross margin as of 2026-08-09 | +47.3% | +40.3% | AMPH higher |
| Operating margin as of 2026-08-09 | +16.2% | -0.9% | AMPH higher |
| ROE as of 2026-08-09 | +10.2% | -2.8% | AMPH higher |
| ROA as of 2026-08-09 | +4.8% | -1.1% | AMPH higher |
| Debt / equity as of 2026-08-09 | 0.79 | 0.94 | AMPH lower |
| Revenue growth (YoY) as of 2026-08-09 | -1.4% | +4.4% | VTRS higher |
| Revenue CAGR (3y) SEC XBRL | +13.0% | -4.2% | AMPH higher |
| Dividend yield as of 2026-08-09 | n/a | +2.7% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-09 | 0.91 | 0.87 | |
| 1-year return as of 2026-08-07 close | -3.9% | +75.0% | VTRS higher |
Fundamentals: market data, as of 2026-08-09. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.